VO2 Max, GLP-1 Costs, and Is Walking Really Enough? | Barbell Medicine Direct Line | March 2026

Why It Matters

Understanding the limits of VO2 max as a sole health metric prevents misdirected training, while navigating GLP‑1 pricing realities ensures broader patient access to life‑changing therapies.

Key Takeaways

• VO2 max differs from broader cardiorespiratory fitness measures.
• Targeting VO2 max alone may neglect other health‑beneficial training.
• Performance‑based tests can reliably track fitness without exact VO2 max.
• GLP‑1 drug prices remain high but manufacturer programs are lowering costs.
• Generic or biosimilar GLP‑1s unlikely before 2030s due to patents.

Summary

The Barbell Medicine Direct Line episode tackled two hot topics for health‑focused consumers: the relevance of VO2 max versus broader cardiorespiratory fitness metrics for longevity, and the soaring cost of GLP‑1 obesity drugs. Dr. Jordan Flagenbomb and Dr. Austin Barack dissected the scientific literature, noting that most longevity studies rely on exercise tolerance tests or MET‑based estimates rather than direct VO2 max measurements, and that Dr. Peter Aia’s percentile targets may overstate the precision of the metric.

Both doctors agreed that while VO2 max is a useful indicator of central aerobic capacity, it captures only a slice of overall cardiorespiratory health. They warned that training programs fixated on boosting a single number can sideline other effective modalities, drawing an analogy to grip‑strength metrics in strength training. Cited evidence includes a 2022 Gemma Network analysis using METs and a 1989 JAMA treadmill‑time study, underscoring that performance‑based tests correlate well with VO2 max without requiring costly metabolic carts.

The conversation then shifted to GLP‑1 therapies such as Ozempic, Wegovy, and Zepbound. Despite list prices exceeding $1,000 per month, manufacturers now offer direct‑access programs that can reduce out‑of‑pocket costs to $149‑$299 monthly. However, the panel highlighted structural barriers to generic or biosimilar entry: peptide‑based structures, extensive patent portfolios, and device (pen) protections mean true generics are unlikely before the 2030s.

For clinicians and consumers, the takeaway is twofold: adopt a multi‑metric approach to aerobic fitness rather than obsess over VO2 max, and explore manufacturer assistance programs while recognizing that affordable generic GLP‑1 options remain a long‑term prospect. Both issues illustrate how nuanced science and market dynamics shape real‑world health outcomes.

Original Description

This is a free preview of the March 2026 Barbell Medicine Direct Line AMA. In this clip, Dr. Jordan Feigenbaum and Dr. Austin Baraki cover three of the most-asked questions in evidence-based fitness:

• VO2 Max vs. Cardiorespiratory Fitness: Is Peter Attia overstating his VO2 max claim? We break down the difference between VO2 max and CRF, and why the distinction matters for how you train.

• GLP-1 Medication Costs in 2026: Manufacturer direct programs have brought cash-pay prices to $149–449/month. Dr. Baraki explains what’s available now and where the market is heading.

• Is Walking Enough? If you’re already hitting 7,000–10,000 steps per day, do you still need formal conditioning? The honest answer depends on what you’re trying to accomplish.

Get the full nearly two hour episode — including exercise after heart attack, resistance training for RA, exercise after cancer, fracture healing, and a 30-minute lightning round — at https://barbellmedicine.supercast.com/

Timestamps:

0:00 — Introduction

3:11 — VO2 Max vs. Cardiorespiratory Fitness

13:56 — GLP-1 Costs: What you should actually be paying now

21:28 — Is Walking Enough for Cardiovascular Health?

Next Steps:

For evidence-based resistance training programs: barbellmedicine.com/training-programs

For individualized training consultation: barbellmedicine.com/coaching

Explore our full library of articles on health and performance: barbellmedicine.com/resources

To consult with Drs. Baraki or Feigenbaum email us at [e-mail]

Resources:

JAMA Network Open — Cardiorespiratory Fitness & Long-term Mortality (Mandsager et al.) — Exercise capacity (METs) and longevity — the foundational CRF/mortality study cited in the episode https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2707428

JAMA (1989) — Blair et al. — Physical fitness and all-cause mortality: a prospective study of healthy men and women https://jamanetwork.com/journals/jama/fullarticle/379243

Barbell Medicine Vital Five — Multi-modal CRF benchmarks and longevity targets https://www.barbellmedicine.com/vital-5-action-plan/

Lilly Direct — Zepbound (tirzepatide) — Manufacturer direct program ($299–449/month) https://www.lillydirect.com/zepbound

NovoCare — Wegovy (semaglutide) — Manufacturer savings program ($149–349/month) https://www.novocare.com/patient/medicines/wegovy.html

Orforglipron — Eli Lilly oral GLP-1 — What to know about orforglipron (small-molecule oral GLP-1 agonist, pending FDA approval) https://www.lilly.com/news/stories/what-to-know-about-orforglipron